Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

× No keyword cloud information.

72 in total

1. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.

Authors: Fotios Loupakis; Emilio Bria; Vanja Vaccaro; Federica Cuppone; Michele Milella; Paolo Carlini; Chiara Cremolini; Lisa Salvatore; Alfredo Falcone; Paola Muti; Isabella Sperduti; Diana Giannarelli; Francesco Cognetti
Journal: J Exp Clin Cancer Res Date: 2010-05-26

2. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer.

Authors: Brandon G Smaglo; Jimmy Hwang
Journal: J Gastrointest Oncol Date: 2013-09

3. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.

Authors: Yosuke Horita; Yasuhide Yamada; Ken Kato; Yoshinori Hirashima; Kouhei Akiyoshi; Kengo Nagashima; Takako Nakajima; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal: Int J Clin Oncol Date: 2011-10-15 Impact factor: 3.402

4. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.

Authors: Ludmila Katherine Martin; Anthony Cucci; Lai Wei; Jeffrey Rose; Marlo Blazer; Carl Schmidt; Hooman Khabiri; Mark Bloomston; Tanios Bekaii-Saab
Journal: Clin Colorectal Cancer Date: 2012-01-24 Impact factor: 4.481

Review 5. Review of systemic therapies for locally advanced and metastatic rectal cancer.

Authors: Patrick Yaffee; Arsen Osipov; Carlyn Tan; Richard Tuli; Andrew Hendifar
Journal: J Gastrointest Oncol Date: 2015-04

6. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors: Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal: Int J Clin Oncol Date: 2011-10-15 Impact factor: 3.402

Review 7. The role of targeted therapy in the treatment of advanced colorectal cancer.

Authors: Marwan Fakih
Journal: Curr Treat Options Oncol Date: 2009-02-24

8. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.

Authors: Michihiro Yoshida; Takaya Shimura; Mikinori Sato; Masahide Ebi; Takahiro Nakazawa; Hiromitsu Takeyama; Takashi Joh
Journal: J Cancer Res Clin Oncol Date: 2012-10-26 Impact factor: 4.553

9. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors: Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544

10. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

Authors: Heather Taffet Gold; Michael J Hall; Victoria Blinder; Bruce R Schackman
Journal: Cancer Date: 2009-09-01 Impact factor: 6.860